Saresella and colleagues (2020) and Liang and colleagues (2020) showed that AD patients have elevated levels of sST2 (measured by ELISA), which ameliorates the physiological effects of IL-33 and can contribute to the decline of cognitive function in the course of AD [156,157]. The gene discussed is IL33; the disease is Alzheimer disease.